etomoxir has been researched along with cardiovascular agents in 6 studies
| Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 260 | 8 | 93 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chirkov, YY; Chirkova, LP; Horowitz, JD; Kennedy, JA; Murphy, GA; Willoughby, SR | 1 |
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Frenneaux, M; Horowitz, J; Lee, L | 1 |
| Inglis, S; Stewart, S | 1 |
| Abozguia, K; Clarke, K; Frenneaux, M; Lee, L | 1 |
| Heggermont, WA; Heymans, S; Papageorgiou, AP; van Bilsen, M | 1 |
5 review(s) available for etomoxir and cardiovascular agents
| Article | Year |
|---|---|
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Enzyme Inhibitors; Epoxy Compounds; Glucose; Humans; Hypoglycemic Agents; Insulin; Myocardial Ischemia; Myocardium; Perhexiline; Piperazines; Potassium; Ranolazine; Trimetazidine | 2004 |
Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Topics: Acetanilides; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Monitoring; Epoxy Compounds; Fatty Acids; Half-Life; Humans; Metabolic Clearance Rate; Nurse's Role; Nursing Assessment; Patient Education as Topic; Patient Selection; Perhexiline; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2006 |
Modification of myocardial substrate use as a therapy for heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Cardiovascular Agents; Energy Metabolism; Epoxy Compounds; Fatty Acids, Nonesterified; Glycine; Heart; Humans; Myocardium; Oxygen; Perhexiline; Piperazines; Ranolazine; Trimetazidine | 2006 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Perhexiline; Ranolazine; Stroke Volume; Trimetazidine | 2016 |
1 other study(ies) available for etomoxir and cardiovascular agents
| Article | Year |
|---|---|
Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
Topics: Adult; Aged; Amiodarone; Blood Platelets; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Case-Control Studies; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Female; Humans; Male; Middle Aged; Perhexiline; Platelet Aggregation; Trimetazidine; Vasodilator Agents | 1998 |